Identification of cooperative genes for E2A-PBX1 to develop acute lymphoblastic leukemia.

Cancer Sci

Department of Disease Model, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.

Published: July 2016

AI Article Synopsis

  • E2A-PBX1 is a chimeric gene linked to acute lymphoblastic leukemia (ALL) found in cases involving a specific chromosomal translocation (t(1;19)), but it alone doesn't cause leukemia in experimental mice.
  • Conditional knock-in mice were created to study E2A-PBX1, and even with its expression, no leukemia developed, indicating other genetic factors are necessary for the disease.
  • The study found that retroviral infections induced various types of ALL in these mice, identifying specific genes like Gfi1, Mycn, and particularly Zfp521, which cooperate with E2A-PBX1 to contribute to B-cell leukemia, suggesting ZNF521 may also play a significant role in

Article Abstract

E2A-PBX1 is a chimeric gene product detected in t(1;19)-bearing acute lymphoblastic leukemia (ALL) with B-cell lineage. To investigate the leukemogenic process, we generated conditional knock-in (cKI) mice for E2A-PBX1, in which E2A-PBX1 is inducibly expressed under the control of the endogenous E2A promoter. Despite the induced expression of E2A-PBX1, no hematopoietic disease was observed, strongly suggesting that additional genetic alterations are required to develop leukemia. To address this possibility, retroviral insertional mutagenesis was used. Virus infection efficiently induced T-cell, B-cell, and biphenotypic ALL in E2A-PBX1 cKI mice. Inverse PCR identified eight retroviral common integration sites, in which enhanced expression was observed in the Gfi1, Mycn, and Pim1 genes. In addition, it is of note that viral integration and overexpression of the Zfp521 gene was detected in one tumor with B-cell lineage; we previously identified Zfp521 as a cooperative gene with E2A-HLF, another E2A-involving fusion gene with B-lineage ALL. The cooperative oncogenicity of E2A-PBX1 with overexpressed Zfp521 in B-cell tumorigenesis was indicated by the finding that E2A-PBX1 cKI, Zfp521 transgenic compound mice developed B-lineage ALL. Moreover, upregulation of ZNF521, the human counterpart of Zfp521, was found in several human leukemic cell lines bearing t(1;19). These results indicate that E2A-PBX1 cooperates with additional gene alterations to develop ALL. Among them, enhanced expression of ZNF521 may play a clinically relevant role in E2A fusion genes to develop B-lineage ALL.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946715PMC
http://dx.doi.org/10.1111/cas.12945DOI Listing

Publication Analysis

Top Keywords

e2a-pbx1
9
acute lymphoblastic
8
lymphoblastic leukemia
8
b-cell lineage
8
cki mice
8
e2a-pbx1 cki
8
enhanced expression
8
gene
5
zfp521
5
identification cooperative
4

Similar Publications

Comprehensive summary: the role of PBX1 in development and cancers.

Front Cell Dev Biol

July 2024

2nd Inpatient Area of Urology Department, China-Japan Union Hospital, Jilin University, Changchun, China.

Article Synopsis
  • * The E2A-PBX1 fusion variant is present in 25% of childhood acute lymphoblastic leukemia patients, highlighting its significance in cancer development.
  • * The study discusses the structure and mechanisms of PBX1 and E2A-PBX1 in promoting cancer, suggesting these proteins as targets for new drug development and recommending E2A-PBX1 for prenatal screening to lower childhood cancer risk.
View Article and Find Full Text PDF

Objectives: To investigate the expression of CD123 in children with acute lymphoblastic leukemia (ALL) and its effect on the clinical characteristics and prognosis of children with B-lineage acute lymphoblastic leukemia (B-ALL).

Methods: A retrospective analysis was conducted on the clinical data of 251 children with ALL who were admitted to the Department of Hematology and Oncology, Children's Hospital of Kunming Medical University, from December 2019 to June 2022. According to the expression of CD123 at initial diagnosis, the children were divided into CD123 group and CD123 group, and the two groups were compared in terms of clinical characteristics and treatment outcome.

View Article and Find Full Text PDF

Epidemiological studies report opposing influences of infection on childhood B-cell acute lymphoblastic leukemia (B-ALL). Although infections in the first year of life appear to exert the largest impact on leukemia risk, the effect of early pathogen exposure on the fetal preleukemia cells (PLC) that lead to B-ALL has yet to be reported. Using cytomegalovirus (CMV) infection as a model early-life infection, we show that virus exposure within 1 week of birth induces profound depletion of transplanted E2A-PBX1 and hyperdiploid B-ALL cells in wild-type recipients and in situ-generated PLC in Eμ-ret mice.

View Article and Find Full Text PDF

Objective: We aimed to investigate the application of CD34 detection in immunophenotypic discrimination and its prognostic relevance in children with acute B-lymphoblastic leukemia (B-ALL).

Patients And Methods: A retrospective analysis was conducted on clinical follow-up data of 105 children with newly diagnosed B-ALL treated at our hospital from January 2022 to December 2023. Based on the expression of CD34 in the bone marrow, patients were divided into a CD34 positive group (positive cells ≥10%) and a CD34 negative group (positive cells <10%).

View Article and Find Full Text PDF

The t(1;19) translocation, encoding the oncogenic fusion protein E2A (TCF3)-PBX1, is involved in acute lymphoblastic leukemia (ALL) and associated with a pre-B-cell receptor (preBCR+) phenotype. Relapse in patients with E2A-PBX1+ ALL frequently occurs in the central nervous system (CNS). Therefore, there is a medical need for the identification of CNS active regimens for the treatment of E2A-PBX1+/preBCR+ ALL.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!